n the last few years, PCSK9 inhibitors have gained an increasing role in the treatment of dyslipidaemias,1 since monoclonal antibodies targeting PCSK9, namely evolocumab and alirocumab, were demonstrated to profoundly reduce plasma LDL-cholesterol levels and the incidence of major cardiovascular events in large randomized clinical trials of highrisk patients.2,

PCSK9 inhibition: not just LDL-cholesterol knock down: a glimmer for cancer / Patrono, C.; Volpe, M.. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - 42:12(2021), pp. 1130-1131. [10.1093/eurheartj/ehab047]

PCSK9 inhibition: not just LDL-cholesterol knock down: a glimmer for cancer

Patrono C.;Volpe M.
2021

Abstract

n the last few years, PCSK9 inhibitors have gained an increasing role in the treatment of dyslipidaemias,1 since monoclonal antibodies targeting PCSK9, namely evolocumab and alirocumab, were demonstrated to profoundly reduce plasma LDL-cholesterol levels and the incidence of major cardiovascular events in large randomized clinical trials of highrisk patients.2,
2021
pcsk-9 inhibitor; dyslipidemia; LDL-cholesterol
01 Pubblicazione su rivista::01b Commento, Erratum, Replica e simili
PCSK9 inhibition: not just LDL-cholesterol knock down: a glimmer for cancer / Patrono, C.; Volpe, M.. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - 42:12(2021), pp. 1130-1131. [10.1093/eurheartj/ehab047]
File allegati a questo prodotto
File Dimensione Formato  
Patrono_PCSK9-inhibition_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 179.29 kB
Formato Adobe PDF
179.29 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1542050
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact